SCHEMBL6841901

SCHEMBL6841901

O=C(c1ccccc1)c1ccc(C(=O)N(CCc2ccccc2)CCc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
HPGD P15428 1/20 0.62
RCE1 Q9Y256 1/20 0.57
LIMK1 P53667 1/20 0.53
LIMK2 P53671 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
LPAR1 Q92633 5/20 0.51
LPAR5 Q9H1C0 5/20 0.51
BACE1 P56817 1/20 0.51
HDAC1 Q13547 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC3 O15379 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
MLYCD O95822 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6842123 0.89 TDP1 (0.56) ALDH1A1HPGDRCE1MEN1KMT2A
SCHEMBL15111089 0.86 RCE1 (0.68) RCE1LIMK1LIMK2MEN1KMT2A
SCHEMBL6843722 0.84 ALDH1A1 (0.68) ALDH1A1HPGDMEN1KMT2ATDP1
SCHEMBL7898126 0.79 ALDH1A1 (0.64) ALDH1A1HPGDMEN1KMT2ANPC1
SCHEMBL11357038 0.78 HPGD (0.70) ALDH1A1HPGDLIMK1LIMK2HDAC1
SCHEMBL9011240 0.78 KMT2A (0.61) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL27474196 0.77 TAAR1 (0.62) ALDH1A1HPGDNPC1RAB9A
SCHEMBL7889494 0.77 ALDH1A1 (0.67) ALDH1A1HPGDMEN1KMT2ANPC1
SCHEMBL15347843 0.77 HPGD (0.63) ALDH1A1HPGDNPC1RAB9AHDAC1
SCHEMBL6311144 0.77 HPGD (1.00) ALDH1A1HPGDMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2004-04-01 US disclosed
EP-1360167-A1 SYMMETRICALLY DISUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING POLY (ADP-RIBOSE) GLYCOHYDROLASE, AND METHODS FOR THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2003-11-12 EP disclosed
US-6635786-B2 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2003-10-21 US disclosed
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2002-09-19 US disclosed
WO-2002057211-A1 SYMMETRICALLY DISUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING POLY (ADP-RIBOSE) GLYCOHYDROLASE, AND METHODS FOR THEIR USE GUILFORD PHARMACEUTICALS, INC. (US) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 ALDH1A1 916/4885HPGD 120/4885RCE1 283/4885
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 ALDH1A1 916/4885HPGD 120/4885RCE1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.